Quantcast

Latest Regulus Therapeutics Inc. Stories

2014-06-25 08:30:45

- New Method of Use Claims Strengthen Patent Estate Covering microRNA-122 Inhibitors for the Treatment of HCV Infection - LA JOLLA, Calif., June 25, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the U.S. Patent and Trademark Office ("USPTO") has granted a patent in the company's exclusively licensed 'Sarnow' patent estate, for claims related to...

2014-06-16 08:28:15

- Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise - LA JOLLA, Calif., June 16, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Paul C. Grint, M.D. to its executive management team as Chief Medical Officer. In his new role, Dr. Grint will be responsible for leading and expanding Regulus'...

2014-05-09 16:24:39

LA JOLLA, Calif., May 9, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus, will present a company overview at the Bank of America Merrill Lynch 2014 Healthcare Conference on Thursday, May 15, 2014 at 12:00 p.m. PDT. The conference is being held at the Encore at the Wynn Las Vegas....

2014-05-08 16:27:14

- 'Clinical Map Initiative' On Track; Advanced RG-101 and RG-012, Expect to Nominate Third microRNA Clinical Candidate by YE 2014 - LA JOLLA, Calif., May 8, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended March 31, 2014 and provided a summary of recent corporate highlights. "In the first quarter of...

2014-05-01 16:32:43

LA JOLLA, Calif., May 1, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2014 on Thursday, May 8, 2014, after the U.S. financial markets close. Regulus will host a conference call and webcast on Thursday, May 8, 2014, at 5:00 pm Eastern Daylight Time to discuss...

2014-04-30 16:30:42

LA JOLLA, Calif., April 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the Deutsche Bank 39(th) Annual Healthcare Conference on Wednesday, May 7, 2014 at 8:40 a.m. EDT. The conference is being held at The...

2014-04-07 08:30:29

- Data Advances microRNA Oncology Portfolio - LA JOLLA, Calif., April 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that three abstracts will be presented in poster presentation sessions during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, CA. An oral presentation will also be...

2014-04-04 16:23:43

LA JOLLA, Calif., April 4, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus, will present a company overview at the 13(th) Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 10:00 am EDT. The conference is being held at The Westin Grand Central Hotel in New York...

2014-03-25 08:29:32

LA JOLLA, Calif., March 25, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and the Alport Syndrome Foundation ("ASF"), a non-profit corporation, announced today they are working together to raise awareness of Alport Syndrome, a life-threatening genetic kidney disease driven by genetic mutations with no approved therapy. This month, Regulus will join the...

2014-03-05 08:28:56

- Study Designed to Demonstrate Human Proof-of-Concept Results by YE 2014 - LA JOLLA, Calif., March 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has commenced dosing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122") in healthy volunteer subjects in a Phase I clinical study. The primary objective of the study...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related